Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens

International Journal of Gynecological Pathology

Volumn 15, Issue 1, 1996, Pages 17-22

  Cohen, Ilan ^a   Figer, Arie ^b   Altaras, Marco M ^a   Tepper, Ron ^a   Shapira, Jeremiah ^a   Cordoba, Mario ^a   Yigael, Dror ^a   Arbel, Yael ^a   Beyth, Yoram ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Endometrium; Progestogen; Tamoxifen

Indexed keywords

GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DECIDUALIZATION; ENDOMETRIUM ATROPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY;

EID: 0030028352     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199601000-00003     Document Type: Article

References (45)

1. Baum M, Brinkley DM, Dosset JA. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Br J Cancer 1988;57:608-11.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
4. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-38.
5. Hardell L. Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 1988;3:563.
6. Fornader T, Cedermak B, Mattson A, et al.. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;21:117-20.
7. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-31.
8. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet 1989;1:375.
9. Atlante G, Pozzi M, Vincenzoni C, Vincenzoni C, Vocaturo G. Four case reports presenting new acquisitions on the association of breast and endometrial cancer. Gynecol Oncol 1990;37:378-80.
10. Malfetano JH. Tamoxifen: associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82-4.
11. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 1990; 90:207-8.
12. Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer [Editorial]. Cancer 1990;65:1463-64.
13. Cross SS, Ismail SM. Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy: case report. Br J Obstet Gynaecol 1990;97:190-2.
14. Gal D, Kopel S, Bashevkim M, Lebowicz I, Lew R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: a preliminary report. Gynecol Oncol 1991;42:120-3.
15. De Muylder X, Neven P, De Somer M. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991;36:127-9.
16. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radio- therapy for early breast cancer. J Natl Cancer Inst 1991;83: 1013-7.
17. Segna RA, Dottino PR, Deligdisch L, Cohen CJ. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416-8.
18. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JC, Livolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79:111-6.
19. Cohen I, Shapira Y, Altaras M, Cordoba M, Beyth Y. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol 1992;99:773-4.
20. Altaras M, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993;49:255-8.
21. Cohen I, Rosen DJD, Shapira J, Cordoba M, Altaras M, Dror Y, Beyth Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-70.
22. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-4.
23. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;1:485-90.
24. Seoud MA-F, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165-9.
25. Cohen I, Rosen DJD, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52:185-9.
26. Nasri MN, Shepard JH, Stechall ME, Lowe DG, Chard T. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991;98:470-5.
27. Lazebnik N, Hill LM, Robinson TM. Transvaginal sonography in a woman treated with megestrol acetate for breast cancer. J Ultrasound Med 1994;13:653-4.
28. Muss HB, Wells HB, Paschold EH, et al.. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis, a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6:1098-106.
29. Ober WB. Synthetic progestagen-oestrogen preparations and endometrial morphology. J Clin Pathol 1966;19:138-43.
30. Gold JJ, Josimovich JB. Gynecologic endocrinology, 3rd ed. Hagerstown: Harper and Row, 1980:263.
31. Clement PB, Scully RE. Idiopathic postmenopausal decidual reaction of the endometrium: a clinicopathologic analysis of four cases. Int J Gynecol Pathol 1988;7:152-61.
32. Tseng L, Gurpide E. Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab 1975;41:402-5.
33. Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility, 4th ed. Baltimore: Williams and Wilkins, 1989:26.
34. Zaino RJ, Satyaswaroop PG, Mortel R. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res 1985;45:539-41.
35. Gorodeski GI, Beery R, Lunenfeld B, Geier A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fertil Steril 1992; 57:390-7.
36. Nasri MM, Coast GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333-6.
37. Lin MC, Gosnik BB, Wolf SL, et al.. Endometrial thickness after menopause: effect of hormone replacement. Radiology 1991;180:427-31.
38. Cohen I, Rosen DJD, Tepper R, et al. Ultrasonographic evaluation of the endometrium with correlation to endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993;12:275-80.
39. Cohen I, Tepper R, Rosen D, et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal treated breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994;55:138-43.
40. Neven P, Shepard JH, Lowe DG. Tamoxifen and the gynecologist. Br J Obstet Gynaecol 1993;100:893-7.
41. Kistner RW. Treatment of hyperplasia and carcinoma in situ of the endometrium. Clin Obstet Gynecol 1982;25:63-72.
42. Jordan VC. Laboratory evidence to support the use of long-term adjuvant tamoxifen therapy for breast cancer. Horm Res 1984;32(suppl):261-5.
43. Wallgran A, Barae E, Carstensen J. Should adjuvant tamoxifen be given for several years in breast cancer? In: SE Jones, SE Salmon, eds. Adjuvant therapy of cancer, vol. 4. New York: Grune and Stratton, 1984:331-7.
44. Neven P. Tamoxifen and endometrial lesions. Lancet 1993;342:452.
45. Hulka BS, Chambless LE, Kaufman DG, Fowler WL, Grenberg G. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982;47:475-7.